| Stein, Mark |
PRIME-CUT, NCT03951831: REGN2810 Followed by Chemoimmunotherapy for Newly Metastatic Hormone-sensitive Prostate Cancer |
|
|
| Active, not recruiting | 2 | 20 | US | REGN2810, Cemiplimab, Degarelix, Firmagon, Leuprolide Acetate, Lupron, Docetaxel, Taxotere | Mark Stein, Regeneron Pharmaceuticals | Prostate Cancer Metastatic | 03/24 | 04/28 | | |
NCT04631744: Cabozantinib in Patients With Metastatic Castrate Resistant Prostate Cancer (mCRPC) |
|
|
| Recruiting | 2 | 30 | US | Cabozantinib | Weill Medical College of Cornell University, Exelixis | Prostate Cancer | 07/26 | 07/27 | | |
Cyto-KIK, NCT04322955: CYTO Reductive Surgery in Kidney Cancer Plus Immunotherapy and Targeted Kinase Inhibition |
|
|
| Recruiting | 2 | 48 | US | Cabozantinib, XL184, Nivolumab, BMS-936558, Cytoreductive nephrectomy | Mark Stein, Exelixis, Bristol-Myers Squibb | Kidney Cancer, Renal Cell Carcinoma | 05/26 | 02/27 | | |
SAABR, NCT04262154: Study of Abiraterone Acetate or Enzalutamide, Atezolizumab, GnRH Analog and Radiation Therapy in Men with Newly Diagnosed Hormone-sensitive Prostate Cancer |
|
|
| Active, not recruiting | 2 | 28 | US | Atezolizumab, Abiraterone, Prednisone, GnRH analog, Stereotactic Body Radiotherapy (SBRT), Enzalutamide, Follow up | Memorial Sloan Kettering Cancer Center, Genentech, Inc., Stand Up To Cancer | Metastatic Prostate Cancer | 09/26 | 09/26 | | |
| Active, not recruiting | 1/2 | 60 | US | Nivolumab, Opdivo®, Degarelix, Firmagon®, BMS-986253, HuMax IL-8 | Mark Stein, Bristol-Myers Squibb | Prostate Cancer, Adenocarcinoma of the Prostate | 05/24 | 01/25 | | |
NCT05553639: HB-302/HB-301 Therapy in Participants With Metastatic Castration-Resistant Prostate Cancer |
|
|
| Terminated | 1/2 | 12 | US | HB-302/HB-301 Alternating 2-Vector Therapy | Hookipa Biotech GmbH | Prostate Cancer Metastatic | 04/24 | 04/24 | | |
NCT04946370: Phase I/II Trial of Pembrolizumab and Androgen-receptor Pathway Inhibitor With or Without 225Ac-J591 for Progressive Metastatic Castration Resistant Prostate Cancer |
|
|
| Recruiting | 1/2 | 76 | US | 225Ac-J591, Pembrolizumab, Androgen receptor pathway inhibitor, 68Ga-PSMA-11, 68Ga-PSMA-HBED-CC | Weill Medical College of Cornell University, United States Department of Defense, Merck Sharp & Dohme LLC | Prostate Cancer | 06/26 | 06/28 | | |
| Active, not recruiting | 1/2 | 200 | Europe, US | BT7480, Nivolumab | BicycleTx Limited | Advanced Solid Tumor | 09/25 | 12/25 | | |
NCT02744287: Safety and Activity Study of PSCA-Targeted CAR-T Cells (BPX-601) in Subjects With Selected Advanced Solid Tumors |
|
|
| Suspended | 1/2 | 151 | US | BPX-601, Rimiducid, AP1903 | Bellicum Pharmaceuticals | Metastatic Castration-resistant Prostate Cancer, Metastatic Prostate Cancer | 10/25 | 02/26 | | |
|
|
|
|
|
| Recruiting | 1/2 | 144 | US | ONC-392, A humanized anti-CTLA4 IgG1 monoclonal antibody, Gotistobart, lutetium Lu 177 vipivotide tetraxetan, IV infusion, Q6W for up to 6 doses., Pluvicto | OncoC4, Inc., Prostate Cancer Clinical Trials Consortium | Metastatic Castration-resistant Prostate Cancer | 06/26 | 06/27 | | |
NCT05617040: Prime-boost Immunotherapeutic Trial in Men With Biochemical Recurrence After Definitive Local Therapy for Prostate Cancer |
|
|
| Active, not recruiting | 1/2 | 144 | US | ChAdOx1-PCAQ, MVA-PCAQ | Barinthus Biotherapeutics | Prostate Cancer | 08/26 | 04/27 | | |
| Terminated | 1/2 | 21 | Europe, US | ONCT-534, GTx-534, UT-34 | Oncternal Therapeutics, Inc | Metastatic Castration-resistant Prostate Cancer | 09/24 | 09/24 | | |
NCT05867420: A Study of ASKG915 in Patients With Selected Advanced Solid Tumors. |
|
|
| Recruiting | 1 | 104 | US | ASKG915 | AskGene Pharma, Inc., Jiangsu Aosaikang Pharmaceutical Co., Ltd. | Advanced Solid Tumors | 03/24 | 12/25 | | |
NCT05304858: Tumor Microenvironment Analysis of Prostate Cancer Metastasis |
|
|
| Recruiting | N/A | 16 | US | Biopsy | Columbia University, Janssen Pharmaceuticals | Recurrent Prostate Cancer | 07/24 | 07/24 | | |
| Cook, Edwin |
| No trials found |
| Phillips, Heather |
| No trials found |
